Posted by Michael Wonder on 08 Jun 2023
SAR443579/IPH6101 receives FDA fast track designation in the US for the treatment of haematological malignancies
8 June 2023 - SAR443579, ANKET platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi.
Innate Pharma SA is pleased to share Sanofi’s news that the US FDA has granted fast track designation for SAR443579/IPH6101 for the treatment of haematological malignancies.
